Effect of fibrin sealant composition on human neutrophil chemotaxis.
The use of fibrin sealants offers one of the most physiologically compatible approaches to preventing postoperative adhesions. Although a number of fibrin sealant formulations have been developed, little is known about how the various components of these preparations affect the wound-healing process. Because one of the key steps in wound healing is the migration of phagocytic leukocytes, such as neutrophils, into the site of injury, we performed studies to characterize systematically the effects of various fibrin sealant components on neutrophil chemotaxis. Using a transwell chemotaxis assay, we found that increasing fibrin concentration resulted in an inhibition of the ability of the cells to migrate through the clots in a dose-dependent manner, and at fibrin clot concentrations >2.0 mg/mL chemotaxis was completely blocked. Factor XIII crosslinking of the clots also had a significant impact on neutrophil chemotaxis, and sealant preparations deficient in Factor XIII allowed neutrophil migration at much higher fibrin concentrations. The presence of various other fibrin sealant components such as plasminogen and fibrinolysis inhibitors (aprotinin and tranexamic acid) did not have any significant effects on the ability of neutrophils to migrate through fibrin clots as compared to control clots without these components. Overall, these studies show that the composition of fibrin sealant preparations can significantly affect neutrophil migration into the site of injury, which could possibly influence the wound healing process.
Hanson
Angela J
AJ
Department of Veterinary Molecular Biology, Montana State University, Bozeman 59717, USA.
Quinn
Mark T
MT
D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005176:Factor XIII / Q000494:pharmacology; D015718:Fibrin Tissue Adhesive / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D020556:Neutrophil Infiltration / Q000187:drug effects; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects*; D010958:Plasminogen / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D000267:Tissue Adhesions / Q000188:drug therapy / Q000276:immunology
D015718:Fibrin Tissue Adhesive; D011480:Protease Inhibitors; D010958:Plasminogen; D005176:Factor XIII